High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcγR triggering

Annals of the Rheumatic Diseases

Volumn 63, Issue 6, 2004, Pages 696-702

  Radstake, T R D J ^a,b   Van Lent, P L E M ^b   Pesman, G J ^b   Blom, A B ^b   Sweep, F G J ^b   Ronnelid J ^c   Adema, G J ^b   Barrera, P ^b   Van Den Berg, W B ^b  

^a University Medical Centre ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD; CELL MATURATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MEASUREMENT; MOLECULAR MECHANICS; MONOCYTE; PATIENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RHEUMATOID ARTHRITIS; TH1 CELL; TH2 CELL;

ARTHRITIS, RHEUMATOID; CYTOKINES; DENDRITIC CELLS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKINS; RADIOIMMUNOASSAY; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442646640     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.010033     Document Type: Article

References (53)

1. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
2. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
3. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 1999;38(suppl 2):3-7.
4. Isomaki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997;29:499-507.
5. Vervoordeldonk MJ, Tak PP. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:208-17.
6. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
7. van der Graaff WL, Prins AP, Dijkmans BA, van Lier RA. Prognostic value of Th1/Th2 ratio in rheumatoid arthritis. Lancet 1998;351:1931.
8. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001;15:677-91.
9. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263-6.
10. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8.
11. Steinman RM, Nussenzweig MC. Inaugural article: avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002;99:351-8.
12. Leung BP, Conacher M, Hunter D, McInnes IB, Liew FY, Brewer JM. A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol 2002;169:7071-7.
13. Li TF, Mandelin J, Hukkanen M, Lassus J, Sandelin J, Santavirta S, et al. Dendritic cells in rheumatoid synovial membrane after total removal of the hyaline articular cartilage. Rheumatology (Oxford) 2002;41:319-23.
14. Page G, Lebecque S, Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2992;168:5333-41.
15. Radstake TR, Blom AB, Sloetjes AW, van Gorselen EO, Pesman GJ, Engelen L, et al. Elevated FcγRII expression and aberrant TNF-α production by mature DCS of patients with active rheumatoid arthritis (RA). Ann Rheum Dis (in press).
16. Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity. J Rheumatol 2002;29:454-61.
17. Tsark EC, Wang W, Teng YC, Arkfeld D, Dodge GR, Kovats S. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002;169:6625-33.
18. Amigorena S, Bonnerot C. Fc receptor signaling and trafficking: a connection for antigen processing. Immunol Rev 1999;172:279-84.
19. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996;157:541-8.
20. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999;72:255-324.
21. Pettit AR, MacDonald KP, O'Sullivan B, Thomas R. Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum 2000;43:791-800.
22. Dijstelbloem HM, van De Winkel JG, Kallenberg CG. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 2001;22:510-16.
23. Salmon JE, Pricop L. Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum 2001;44:739-50.
24. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
25. Mannik M, Nardella FA, Sasso EH. Rheumatoid factors in immune complexes of patients with rheumatoid arthritis. Springer Semin Immunopathol 1988;10:215-30.
26. Blom AB, van Lent PL, van Vuuren H, Holthuysen AE, Jacobs C, van de Putte LB, et al. FcgammaR expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA). Arthritis Res 2000;2:489-503.
27. van Lent PL, van Vuuren AJ, Blom AB, Holthuysen AE, van de Putte LB, van de Winkel JG, et al. Role of Fc receptor gamma chain in inflammation and cartilage damage during experimental antigen-induced arthritis. Arthritis Rheum 2000;43:740-52.
28. van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, van de Putte LB, et al. Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 2001;159:2309-20.
29. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fcgamma receptors. J Immunol 2002;168:3697-701.
30. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002,72:101-6.
31. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001;107:1275-84.
32. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001;166:3499-505.
33. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
34. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, et al. Identification of DCS-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses [see comments]. Cell 2000;100:575-85.
35. Van Der Meer JW, Endres S, Lonnemann G, Cannon JG, Ikejima T, Okusawa S, et al. Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro.
36. Drenth JP, Van Uum SH, van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van Der Meer JW. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol 1995;79:1497-503.
37. Helle M, Boeije L, de Groot E, de Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991;138:47-56.
38. Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003;62:37-42.
39. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997;12:6-14.
40. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001;30(suppl 2):1-6.
41. Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000;43:608-16.
42. Blom AB, Radstake TR, Holthuysen AE, Sloetjes A, Pesman GJ, Sweep CG, et al. Increased expression of FγRII and III expression on macrophages of RA patients results in higher TNFα and MMP production. Arthritis Rheumatism 2003;48:1002-14.
43. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394-400.
44. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002;73(suppl):S19- S22.
45. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001;22:41-7.
46. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999;189:179-85.
47. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002;195:1653-9.
48. Jiang Y, Hirose S, Abe M, Sanokawa-Akakura R, Ohtsuji M, Mi X, et al. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 2000;51:429-35.
49. Yasuda K, Sugita N, Yamamoto K, Kobayashi T, Yoshie H. Seven single nucleotide substitutions in human Fcγ receptor IIB gene. Tissue Antigens 2001;58:339-42.
50. Pascare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
51. Mackay I, Rosen F. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
52. Kanik K, Yarbora C, Naparstek Y, Plots P, Wilder R. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum 1996;39:1027-29.
53. Maksymowych W, Avina-Zubieta A, Luong M, Russell A. High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol 1996;14:657-60.